Overview

Long-term Study With Clevudine

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

A open-labeled phase lV study with 96 weeks of treatment period. The purpose of this study is to investigate safety and efficacy of clevudine in patients chronically infected with hepatitis B virus, HBeAg positive or negative.

Phase:

Phase 4

Details

Lead Sponsor:

Bukwang Pharmaceutical

Treatments:

Clevudine